Limited develops the next generation of antibody molecules:
Human Domain Antibodies. Domain Antibodies™ (dAbs™) are therapeutic molecules that have benefits of both small molecules and conventional antibodies. Like small molecules, dAbs are small in size and highly stable, resulting in a choice of therapeutic formats, delivery formulations and manufacture options. And like human antibodies, dAbs can be designed to have specificity and high affinity for the biological target of interest. Therapeutic leads include dAbs that uniquely neutralise (but not agonise) cytokine receptor targets, and Dual Targeting dAbs that can bind two therapeutic targets in one easily produced molecule. Due to its exclusive intellectual property and technology position for Domain Antibodies, Domantis is the only company capable of fully exploiting human Domain Antibodies.
As of January 5, 2007 Domantis Limited is a wholly owned subsidiary of GlaxoSmithKline
For enquiries about vacancies at Domantis, please visit the GSK career site at: http://www.gsk.com/careers/index.htm
For general enquiries, please dial +44-1223 226900 or email to reception@domantis.com
AlbudAb, AlbudAbs, Domain Antibody, Domain Antibodies, Domain Antibody Therapeutics, dAb and dAbs are trademarks of the GlaxoSmithKline group of companies.
